CD274 and cancer: In another Phase I trial conducted in surgically resected PDAC patients, sequential administration of PD-L1 immune checkpoint inhibitors, individualized mRNA vaccine encompassing 20 different neoantigens, and four chemotherapy regimens resulted in half of the vaccine recipients, all of whom had expanded neoantigen-specific T cells after vaccination, remaining cancer-free [411].